carbachol has been researched along with Focal Segmental Glomerulosclerosis in 2 studies
Carbachol: A slowly hydrolyzed CHOLINERGIC AGONIST that acts at both MUSCARINIC RECEPTORS and NICOTINIC RECEPTORS.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bousquet, SM | 1 |
Monet, M | 1 |
Boulay, G | 1 |
Winn, MP | 1 |
Conlon, PJ | 1 |
Lynn, KL | 1 |
Farrington, MK | 1 |
Creazzo, T | 1 |
Hawkins, AF | 1 |
Daskalakis, N | 1 |
Kwan, SY | 1 |
Ebersviller, S | 1 |
Burchette, JL | 1 |
Pericak-Vance, MA | 1 |
Howell, DN | 1 |
Vance, JM | 1 |
Rosenberg, PB | 1 |
2 other studies available for carbachol and Focal Segmental Glomerulosclerosis
Article | Year |
---|---|
Protein kinase C-dependent phosphorylation of transient receptor potential canonical 6 (TRPC6) on serine 448 causes channel inhibition.
Topics: Amino Acid Substitution; Carbachol; Carcinogens; Cell Proliferation; Glomerulosclerosis, Focal Segme | 2010 |
A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis.
Topics: Amino Acid Substitution; Angiotensin II; Calcium; Calcium Channels; Calcium Signaling; Carbachol; Ce | 2005 |